<?xml version='1.0' encoding='utf-8'?>
<document id="8957145"><sentence text="Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users."><entity charOffset="44-53" id="DDI-PubMed.8957145.s1.e0" text="rifabutin" /><entity charOffset="58-67" id="DDI-PubMed.8957145.s1.e1" text="methadone" /><pair ddi="false" e1="DDI-PubMed.8957145.s1.e0" e2="DDI-PubMed.8957145.s1.e0" /><pair ddi="false" e1="DDI-PubMed.8957145.s1.e0" e2="DDI-PubMed.8957145.s1.e1" /></sentence><sentence text="Rifampin, an agent known to decrease the half-life of methadone, and rifabutin are two rifamycins that are structurally similar and share mechanisms of action"><entity charOffset="0-8" id="DDI-PubMed.8957145.s2.e0" text="Rifampin" /><entity charOffset="54-63" id="DDI-PubMed.8957145.s2.e1" text="methadone" /><entity charOffset="69-78" id="DDI-PubMed.8957145.s2.e2" text="rifabutin" /><entity charOffset="87-97" id="DDI-PubMed.8957145.s2.e3" text="rifamycins" /><pair ddi="false" e1="DDI-PubMed.8957145.s2.e0" e2="DDI-PubMed.8957145.s2.e0" /><pair ddi="false" e1="DDI-PubMed.8957145.s2.e0" e2="DDI-PubMed.8957145.s2.e1" /><pair ddi="false" e1="DDI-PubMed.8957145.s2.e0" e2="DDI-PubMed.8957145.s2.e2" /><pair ddi="false" e1="DDI-PubMed.8957145.s2.e0" e2="DDI-PubMed.8957145.s2.e3" /><pair ddi="false" e1="DDI-PubMed.8957145.s2.e1" e2="DDI-PubMed.8957145.s2.e1" /><pair ddi="false" e1="DDI-PubMed.8957145.s2.e1" e2="DDI-PubMed.8957145.s2.e2" /><pair ddi="false" e1="DDI-PubMed.8957145.s2.e1" e2="DDI-PubMed.8957145.s2.e3" /><pair ddi="false" e1="DDI-PubMed.8957145.s2.e2" e2="DDI-PubMed.8957145.s2.e2" /><pair ddi="false" e1="DDI-PubMed.8957145.s2.e2" e2="DDI-PubMed.8957145.s2.e3" /></sentence><sentence text=" Hence the possibility of a drug-drug interaction between rifabutin and methadone was evaluated in 24 methadone-maintained, former injecting drug users infected with the human immunodeficiency virus"><entity charOffset="58-67" id="DDI-PubMed.8957145.s3.e0" text="rifabutin" /><entity charOffset="72-81" id="DDI-PubMed.8957145.s3.e1" text="methadone" /><entity charOffset="102-111" id="DDI-PubMed.8957145.s3.e2" text="methadone" /><pair ddi="false" e1="DDI-PubMed.8957145.s3.e0" e2="DDI-PubMed.8957145.s3.e0" /><pair ddi="false" e1="DDI-PubMed.8957145.s3.e0" e2="DDI-PubMed.8957145.s3.e1" /><pair ddi="false" e1="DDI-PubMed.8957145.s3.e0" e2="DDI-PubMed.8957145.s3.e2" /><pair ddi="false" e1="DDI-PubMed.8957145.s3.e1" e2="DDI-PubMed.8957145.s3.e1" /><pair ddi="false" e1="DDI-PubMed.8957145.s3.e1" e2="DDI-PubMed.8957145.s3.e2" /></sentence><sentence text=" The study was an open-label, drug-drug interaction and safety trial in which patients were followed for 15 days" /><sentence text=" Each patient received rifabutin 300 mg as a single dose concomitantly with their individualized methadone dosage"><entity charOffset="23-32" id="DDI-PubMed.8957145.s5.e0" text="rifabutin" /><entity charOffset="97-106" id="DDI-PubMed.8957145.s5.e1" text="methadone" /><pair ddi="false" e1="DDI-PubMed.8957145.s5.e0" e2="DDI-PubMed.8957145.s5.e0" /><pair ddi="false" e1="DDI-PubMed.8957145.s5.e0" e2="DDI-PubMed.8957145.s5.e1" /></sentence><sentence text=" No significant differences in methadone peak plasma concentration, time to peak plasma concentration, area under the plasma concentration-time curve, systemic clearance or renal clearance was observed in the presence of rifabutin"><entity charOffset="31-40" id="DDI-PubMed.8957145.s6.e0" text="methadone" /><entity charOffset="221-230" id="DDI-PubMed.8957145.s6.e1" text="rifabutin" /><pair ddi="false" e1="DDI-PubMed.8957145.s6.e0" e2="DDI-PubMed.8957145.s6.e0" /><pair ddi="false" e1="DDI-PubMed.8957145.s6.e0" e2="DDI-PubMed.8957145.s6.e1" /></sentence><sentence text=" Seventy-five percent of the patients reported at least one symptom of narcotic withdrawal during the study, however, these symptoms were mild" /><sentence text=" A relationship between the development of narcotic withdrawal and methadone systemic exposure could not be established"><entity charOffset="67-76" id="DDI-PubMed.8957145.s8.e0" text="methadone" /></sentence><sentence text=" Concurrent administration of rifabutin and methadone appeared to be safe in human immunodeficiency virus-infected injecting drug users maintained on stable doses of methadone and is not expected to produce any significant changes in the pharmacokinetics of methadone in these patients"><entity charOffset="30-39" id="DDI-PubMed.8957145.s9.e0" text="rifabutin" /><entity charOffset="44-53" id="DDI-PubMed.8957145.s9.e1" text="methadone" /><entity charOffset="166-175" id="DDI-PubMed.8957145.s9.e2" text="methadone" /><entity charOffset="258-267" id="DDI-PubMed.8957145.s9.e3" text="methadone" /><pair ddi="false" e1="DDI-PubMed.8957145.s9.e0" e2="DDI-PubMed.8957145.s9.e0" /><pair ddi="false" e1="DDI-PubMed.8957145.s9.e0" e2="DDI-PubMed.8957145.s9.e1" /><pair ddi="false" e1="DDI-PubMed.8957145.s9.e0" e2="DDI-PubMed.8957145.s9.e2" /><pair ddi="false" e1="DDI-PubMed.8957145.s9.e0" e2="DDI-PubMed.8957145.s9.e3" /><pair ddi="false" e1="DDI-PubMed.8957145.s9.e1" e2="DDI-PubMed.8957145.s9.e1" /><pair ddi="false" e1="DDI-PubMed.8957145.s9.e1" e2="DDI-PubMed.8957145.s9.e2" /><pair ddi="false" e1="DDI-PubMed.8957145.s9.e1" e2="DDI-PubMed.8957145.s9.e3" /><pair ddi="false" e1="DDI-PubMed.8957145.s9.e2" e2="DDI-PubMed.8957145.s9.e2" /><pair ddi="false" e1="DDI-PubMed.8957145.s9.e2" e2="DDI-PubMed.8957145.s9.e3" /></sentence><sentence text="" /></document>